touchMEETING HIGHLIGHTS ADVENT at ESPD 2024: Type 2 Inflammation in Atopic Dermatitis and the Benefits of Early Intervention
Join experts Lisa Weibel, Amy Paller, and Eulàlia Baselga as they investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD.
Dr Weibel outlines how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.
Dr Weibel describes how type 2 inflammation can be exacerbated by S. aureus, which is associated with flares and skin infections in AD. She then outlines how type 2 cytokines promote neuronal sensitization and play a critical role in chronic itch in AD.
Dr Weibel outlines the evidence of additional organ involvement in pediatric patients with AD, including implications for mental health, coexisting atopic diseases, cardiovascular risk factors, and bone health.
Dr Paller discusses how early intervention in AD may be an opportunity for disease modification.
In this short panel discussion, Drs Paller, Weibel, and Baselga provide their opinion on the definition of ‘early intervention’ in AD.
Overview & Learning Objectives
Overview
Atopic dermatitis (AD) is a chronic, inflammatory disease characterized by eczematous skin lesions and intense itch, however, the inflammatory processes underlying AD reach far beyond the skin. Uncontrolled chronic disease and inflammation both within and beyond the skin of pediatric AD patients may lead to the development of other atopic diseases, such as asthma and allergic rhinitis, as well as non-atopic comorbidities, like poor bone health and mental health conditions. Development of these extracutaneous health conditions, which may persist into adulthood, can have variable trajectories and contribute to the cumulative life impact of AD.
Join experts Eulàlia Baselga, Amy Paller, and Lisa Weibel as they investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD. The speakers will discuss the potential benefits of treating children with AD early in the disease process.
Learning Objectives
After viewing this activity, participants should be better able to:
- Explore the ways type 2 inflammation contributes to AD disease pathogenesis within and beyond the skin
- Discuss the importance of early intervention in children with AD and the potential for disease modification
Faculty & Disclosures
Dr Eulàlia Baselga
Children’s Hospital Sant Joan de Deu, Barcelona, Spain
Eulàlia Baselga, MD, PhD, is a Pediatric Dermatologist, Head of the Department of Dermatology, at the Children’s Hospital Sant Joan de Deu, Barcelona, Spain. She is a renowned specialist in Pediatric Dermatology and has more than 25 years of experience in the profession and extensive training in different specialty fields.
She is a pediatric dermatologist with a distinguished career in clinical care, teaching, and research. She has combined her clinical work with teaching for 10 years, directing the Master’s degree in Pediatric Dermatology at the Autonomous University of Barcelona. She has also co-directed two doctoral theses and several dissertations. In addition, she is an active researcher and participates in 10 professional and international associations. She has chaired the Spanish Group of Pediatric Dermatology and currently chairs the Hemangioma Investigator Group. She is also a member of the European Society for Pediatric Dermatology.
Dr Eulàlia Baselga discloses: Research funding from Eli Lilly, LEO Pharma, Pfizer, Pierre Fabre, Sanofi and Regeneron, and Venthera (Founder). Speaker and/or consulting fees for AbbVie, Eli Lilly, LEO Pharma, LETI Pharma, Pfizer, Sanofi and Regeneron, Venthera (Founder), and Viatris.
Dr Amy Paller
Northwestern University, Evanston, Illinois, US
Amy Paller, MS, MD, is the Walter J. Hamlin Professor and Chair of Dermatology, Professor of Pediatrics, and Principal Investigator of the NIH-funded Skin Biology and Diseases Resource-based Center (SBDRC) at Northwestern. She is a lead investigator on several landmark trials in pediatric skin diseases and her research focuses on cell-cell communication in inflammatory skin diseases and impaired wound healing. She is current President of the International Society for Pediatric Dermatology, is an author of more than 600 peer-reviewed publications, and has written or edited several major textbooks in dermatology.
Dr Amy Paller discloses: Research funding from AbbVie, Applied Pharma Research, Dermavant, Eli Lilly, Incyte, Janssen, Krystal Biotech, Regeneron, Timber Pharmaceuticals, and UCB. Speaker and/or consulting fees for AbbVie, Abeona Therapeutics, Arcutis Biotherapeutics, ASLAN Pharmaceuticals, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Johnson & Johnson, Krystal Biotech, LEO Pharma, Mitsubishi Tanabe, Nektar Therapeutics, Primus Pharmaceuticals, Procter & Gamble, Sanofi, Seanergy, Regeneron, TWi Biotech, and UCB.
Dr Lisa Weibel
University Children’s Hospital, Zurich, Switzerland
Lisa Weibel is a board certified Pediatrician and Dermatologist. Following her 2-year specialist training in Pediatric Dermatology at Great Ormond Street Hospital for Children in London, she started in 2009 to establish the Pediatric Skin Center in Zurich at the University Children’s Hospital, which today sees >8000 out-patients per year under her lead and engages four additional full-time Pediatric Dermatology Consultants.
Lisa Weibel achieved her MD-Thesis in 2001 and her associate professorship in 2016 from the University of Zurich. Her areas of interest are vascular anomalies, neonatal dermatology, morphea and rare skin diseases. She has published 100 peer-reviewed articles (incl. 58 original articles), is the author of several book chapters in international textbooks and acts as Principal Investigator of investigator-initiated and industry-sponsored clinical trials. Her academic mentoring activities have supported 8 physicians to become full-time Pediatric Dermatologists and she is a popular lecturer at international meetings. Lisa Weibel is a Board Member of the ESPD, the European Hemangioma Task Force, the Swiss Group for Pediatric Dermatology (SGPD), President of the Swiss Group for Vascular Anomalies and Member of the International Society for the Study of Vascular Anomalies (ISSVA).
Dr Lisa Weibel discloses: Research funding from Boehringer Ingelheim, Janssen (PI in clinical trials), and UCB. Speaker, and/or consulting fees for Merz, Novartis, Pierre Fabre, Sanofi, and Regeneron.
